Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.20.2
Strategic Alliances (Details) - USD ($)
1 Months Ended 9 Months Ended 36 Months Ended 69 Months Ended 94 Months Ended
May 05, 2020
Oct. 21, 2019
Oct. 12, 2017
Sep. 30, 2018
Jul. 31, 2018
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2018
Mar. 31, 2013
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront payment from development and license agreement     $ 6,000,000                      
Milestone revenue recognized                 $ 18,376,000   $ 0      
Written termination threshold                 3 months          
VFMCRP | Development and License Agreement                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
License revenue, initial payment           $ 50,000,000                
VFMCRP | Regulatory Milestones                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Additional milestone payment         $ 2,000,000.0                  
VFMCRP | Exclusive Option                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Additional milestone payment to be received           $ 555,000,000                
Pfizer | Products                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone revenue recognized                       $ 0    
Additional milestone payment to be received             $ 275,000,000.0              
Annual height velocity at point in time   12 months                        
Non-refundable and non-creditable upfront payment             295,000,000.0              
Tesaro                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone revenue recognized                 $ 0 $ 0        
Additional milestone payment               $ 85,000,000            
Upfront payment under license agreements               $ 6,000,000.0            
Milestone payment received                         $ 30,000,000  
Period from first commercial sale               12 years            
Minimum | Pfizer | Products                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Each milestone payment             20,000,000.0              
Maximum | Pfizer | Products                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Each milestone payment             $ 90,000,000.0              
Pharmsynthez                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Ownership percentage, equity method                 9.00%   9.00% 9.00%    
Phio Pharmaceuticals                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Maximum milestone payments to be received                           $ 50,000,000.0
Phase Two Initiation                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront payment from development and license agreement       $ 6,000,000                    
Regulatory and Development                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone payment from development and license agreement     31,000,000                      
Sales Revenue                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Milestone payment from development and license agreement     $ 75,000,000                      
Regulatory Milestones | EirGen Pharma Limited                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Maximum milestone payments $ 20,000,000                          
Sales Milestones | EirGen Pharma Limited                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Maximum milestone payments $ 210,000,000